ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:
\n\u2022 as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
\n\u2022 in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
\n\u2022 in combination with docetaxel, for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA.
\n\u2022 in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
\n\u2022 as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of \u2265400 ng\/mL and have been treated with sorafenib.<\/p>\n
Cyramza (ramucirumab) injection for intravenous use Initial U.S. Approval: 2014
\nTo access ramucirumab injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Cyramza (ramucirumab) is a medication used for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, metastatic non small cell lung cancer, and metastatic colorectal cancer.<\/p>\n
This medicine is not (yet) part of our standard product range but we may be able to get it for you. The packaging size and strength below may vary due to product availability. Please contact us to verify price and availability.<\/p>\n
Disease Indications-Colorectal Cancer, Gastric Cancer, Lung Cancer If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cramucirumab injection\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Lilly
\nUsage-Intravenous
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n